Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2471 to 2480 of 2593 total matches.
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
vaccination. N Engl J Med 2021 April 9 (epub). COVID-19 drug safety vaccines ...
On April 13, 2021, the FDA and CDC advised suspending
use of the Johnson & Johnson adenovirus-based
COVID-19 vaccine while the agencies investigate 6
cases of cerebral venous sinus thrombosis (CVST) and
thrombocytopenia that occurred following administration
of the vaccine. In an April 14 emergency meeting,
the Advisory Committee on Immunization Practices
(ACIP) recommended continuing the suspension until
more data become available. About 7 million people in
the US have received the Johnson & Johnson vaccine.
COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
immunization. Med Lett Drugs Ther
2022; 64:159.
3. CDC. Interim clinical considerations for use of COVID-19 ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) as a booster dose in children as young
as 5 years old (Pfizer) or 6 years old (Moderna).
The bivalent Pfizer vaccine had previously been
authorized for use in persons ≥12 years old and the
bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Cosmetic Surgery with Lasers
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997 (Issue 993)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Lasers have been used in dermatology for many years. Recently, however, improvements in laser technology have led to much wider use of lasers for treatment of cosmetic skin problems. Many different types of lasers are available; the US Food and Drug Administration gives manufacturers permission to market laser systems for specific indications.
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to biologic drugs to distinguish reference
products from their biosimilars.
TREATMENT OF HEMOPHILIA A – An X ...
The FDA has approved emicizumab-kxwh (Hemlibra –
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
, have occurred with ferric carboxymaltose.
After administration of the drug, patients should be
monitored ...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 doi:10.58347/tml.2024.1695d | Show Introduction Hide Introduction
Cancer Screening
Treatment Guidelines from The Medical Letter • Dec 01, 2012 (Issue 124)
for women 40-49 years old. Med Lett
Drugs Ther 2009; 51:97.
3. N Shen et al. Mammography in 40-year-old ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may
improve outcomes. Screening tests for some common
cancers are reviewed below.
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002 (Issue 1121)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
A Vaccine for Rotavirus
The Medical Letter on Drugs and Therapeutics • May 21, 1999 (Issue 1053)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
The FDA has approved the marketing of RotaShield, a live oral vaccine for prevention of infantile rotavirus infection. Rotaviruses are segmented double-stranded RNA viruses that are the most common cause of severe diarrhea and dehydration in infants and young children.
Screening for Melanoma
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011 (Issue 1372)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
The Medical Letter®
On Drugs ...
In the absence of randomized studies demonstrating
an impact on mortality, the US Preventive Services
Task Force (USPSTF) has found the evidence insufficient
to recommend a routine whole-body examination
for melanoma and other skin cancers.
An Imaging Agent for Amyloid
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012 (Issue 1394)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1394)
July 9, 2012 ...
The FDA has approved florbetapir F18 (flor bay´ ta pir;
Amyvid – Lilly), an intravenous radioactive diagnostic
agent used with positron emission tomography (PET)
scans, to estimate β-amyloid neuritic plaque density in
adults being evaluated for Alzheimer's disease (AD) or
other causes of cognitive decline.